MedTrace Logo

Pneumococcal Vaccines in Patients With Asthma

NCT03260790 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2021-11-05

Study results available
· View outcomes & findings →

Summary

Investigators are assessing if patients with asthma respond better to the Pneumovax vaccine if they are given Prevnar initially.

Conditions

Interventions

BIOLOGICAL

PCV13

Single 0.5 ml dose of PCV13 administered via intramuscular injection

BIOLOGICAL

PPSV23

Single 0.5 ml dose of PPSV23 administered via intramuscularly or subcutaneously

Sponsors & Collaborators

Principal Investigators

  • Avni Y Joshi · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-01
Primary Completion
2020-12-21
Completion
2020-12-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03260790 on ClinicalTrials.gov